Retatrutide vs Tirzepatide: Which Wins for Weight Loss?
Retatrutide produced more weight loss in trials (~24% vs tirzepatide’s ~21%), but tirzepatide has one decisive advantage: it’s FDA-approved and available by prescription today. Retatrutide is still investigational. Here’s how they actually compare on mechanism, results, dosing and access.
If you want the strongest trial results on paper, retatrutide leads; if you want a treatment you can actually start with a clinician today, tirzepatide wins. Retatrutide is a triple agonist (GLP-1, GIP and glucagon) that reached ~24% mean weight loss in a phase-2 study. Tirzepatide is a dual agonist (GLP-1, GIP) with ~21% in its trials — and, crucially, it’s approved and prescribable now, while retatrutide is not.
Triple agonist vs. dual agonist
The headline difference is how many hormone pathways each one activates. Tirzepatide works on two receptors — GLP-1 and GIP. Retatrutide adds a third, glucagon, which increases energy expenditure on top of appetite suppression. That extra pathway is the leading theory for why retatrutide posted higher weight-loss numbers in early trials.
More power on paper comes with a familiar trade-off: the higher retatrutide doses that drove the most weight loss also drove more gastrointestinal side effects, managed by slow dose titration.
Retatrutide vs tirzepatide comparison
| Retatrutide | Tirzepatide | |
|---|---|---|
| Mechanism | Triple agonist (GLP-1 / GIP / glucagon) | Dual agonist (GLP-1 / GIP) |
| Mean weight loss (trials) | ~24% at highest dose | ~21–22% at highest dose |
| Dosing | Once-weekly injection, titrated to 12 mg | Once-weekly injection, titrated to 15 mg |
| Approval status | Investigational — not approved | FDA-approved |
| How to get it | Clinical trials or unregulated research vendors | Licensed telehealth & pharmacies |
| Best for | Watching next-gen results | Starting supervised treatment now |
Weight-loss figures come from separate phase-2/phase-3 studies and aren’t a head-to-head trial, so treat the comparison as directional.
Retatrutide vs tirzepatide vs semaglutide
Semaglutide is the single-pathway original (GLP-1 only), with ~15% mean weight loss in its trials — effective and the most widely available. The rough ladder people picture is: semaglutide (one pathway) → tirzepatide (two) → retatrutide (three), with weight-loss results tending to climb along that ladder. But only semaglutide and tirzepatide are actually available with a prescription.
Does the “better” one even matter if you can’t get it?
For most people, the real decision isn’t retatrutide vs tirzepatide — it’s “what can I safely start now?” Retatrutide won’t be prescribable until it clears development. Tirzepatide (and semaglutide) can be prescribed today through licensed providers, with medical review and a regulated supply chain.
Want tirzepatide or semaglutide — legally, today?
Compare the top vetted online providers on price, access and support, and start with a clinician-reviewed plan.